

# Pain Management in Newborns



Richard W. Hall, MD<sup>a</sup>, Kanwaljeet J. S. Anand, MBBS, D.Phil., FRCPC<sup>b,\*</sup>

## KEYWORDS

• Analgesia • Sedation • Pain • Stress • NICU • Infant-newborn

## KEY POINTS

- Neonatal pain should be assessed routinely every 4-6 hours or if clinically indicated using context-specific, validated, and objective pain assessment methods.
- Nonpharmacologic and environmental measures are effective for nonspecific distress or acute procedural pain, or can be used as adjunctive therapies for severe ongoing pain.
- Moderate or severe pain requires local/topical anesthetic agents, acetaminophen, NSAIDs, morphine, fentanyl, ketamine, or dexmedetomidine, singly or in combination to avoid side effects or tolerance/withdrawal.
- Evidence-based guidelines for pain management in the Neonatal Intensive Care Unit can be implemented and modified collaboratively using a Quality Improvement approach that is outlined.

## INTRODUCTION

### *Historical Perspective*

Routine assessment and management of neonatal pain has evolved to become an important therapeutic goal in the twenty-first century. During the twentieth century, however, most procedures and clinical practices established in neonatal intensive care units (NICUs) uniformly denied or disregarded the occurrence of neonatal pain. One unfortunate consequence was that infant surgery was conducted routinely with minimal or no anesthesia until the late 1980s.<sup>1,2</sup> Robust responses to painful stimuli were often dismissed as physiologic or behavioral reflexes and not related to the conscious experience of pain.<sup>3</sup> A recent historical analysis suggests that 4 related

---

Disclosure: None.

The authors would like to acknowledge the NIGMS IDeA Program award P30 GM110702 (R.W. Hall), the European Economic Commission – FP7 Programme, and the Oxnard Foundation (K.J.S. Anand) for research funding during the preparation of this article.

<sup>a</sup> Department of Pediatrics/Neonatology, University of Arkansas Hospital, 4305 West Markham Street, Little Rock, AR 72205, USA; <sup>b</sup> Department of Pediatrics/Critical Care Medicine, Le Bonheur Children's Hospital, University of Tennessee Health Science Center, 50 North Dunlap Street, Room 352R, Memphis, TN 38103, USA

\* Corresponding author.

E-mail address: [kanand@uthsc.edu](mailto:kanand@uthsc.edu)

Clin Perinatol 41 (2014) 895–924

<http://dx.doi.org/10.1016/j.clp.2014.08.010>

[perinatology.theclinics.com](http://perinatology.theclinics.com)

0095-5108/14\$ – see front matter © 2014 Elsevier Inc. All rights reserved.

causes contributed to a widely prevalent denial of infant pain<sup>4</sup>: (1) a Darwinian view that held newborns as less evolved human beings; (2) extreme caution and skepticism in interpreting scientific data that suggested infant pain; (3) a reductionistic approach whereby mechanistic behaviorism became the dominant model human psychology in the earlier half of the twentieth century (following J. B. Watson's<sup>5</sup> Behaviorist Manifesto in 1913); and as the behaviorist movement waned, it was followed by (4) an era placing undue emphasis on the structural development of the brain and its responses.<sup>6–8</sup>

This popular precept was challenged by accumulating data on hormonal-metabolic responses to surgical procedures performed under minimal anesthesia,<sup>9,10</sup> which were effectively reduced by giving potent anesthesia,<sup>11–13</sup> the identification of a pain system and initial data on its early development, as well as detailed observations on crying activity and other behaviors of newborns subjected to painful stimuli in the NICU—all of which contributed to a scientific rationale for neonatal pain perception and its clinical implications.<sup>3</sup> Once the existence of neonatal pain was acknowledged and methods for clinical assessment had been validated,<sup>14,15</sup> the stage was set for advances in neonatal pain management.

### ***Importance of Neonatal Pain***

The American Academy of Pediatrics (AAP) and the Canadian Pediatric Society (CPS) updated their guidelines in 2006,<sup>16</sup> recommending that each health care facility treating newborns should establish a neonatal pain control program that includes

- Performing routine assessments to detect neonatal pain
- Reducing the number of painful procedures
- Preventing or treating acute pain from bedside invasive procedures
- Anticipating and treating postoperative pain after surgical procedures
- Avoiding prolonged or repetitive pain/stress during NICU care

Numerous clinical studies have demonstrated that failure to treat pain leads to short-term complications and long-term physiologic, behavioral, and cognitive sequelae, including altered pain processing, attention-deficit disorder, impaired visual-perceptual ability or visual-motor integration,<sup>17–19</sup> and impaired executive functions.<sup>20,21</sup> Conversely, other studies showed needless analgesic therapy prolongs the need for mechanical ventilation, delays feeding, or leads to other sequelae, including impaired brain growth, poor socialization skills, and impaired performance in short-term memory tasks.<sup>17,18</sup> About 460,000 neonates in the United States require care in NICUs each year and are exposed to acute pain from invasive procedures or prolonged pain from surgery or inflammation.<sup>22–24</sup> Assessing neonatal pain is difficult to teach, time and labor intensive, often open to subjective interpretation, and a source of conflict in NICU care.<sup>25–27</sup>

### **PAIN ASSESSMENT**

Current practice requires the nursing staff to make a global pain assessment of neonates or apply validated pain scoring methods before taking appropriate actions to ameliorate newborn pain or discomfort.<sup>24,28,29</sup> The current nursing workload in the NICU does not allow bedside nurses to assess neonatal pain accurately. Many pain scales lump together behavioral, physiologic, and other variables; but these variables may not respond to neonatal pain in similar or specific ways. The interrater reliability and subjectivity of human assessments are further limiting factors in their prevalent use.<sup>27,30–32</sup>

The use of qualitative or subjective methods,<sup>27,32</sup> rather than quantifiable data for neonatal pain assessment, results in inconsistencies and variability in analgesic therapy. Because of a large pharmacokinetic variability of analgesic drugs in neonates, their pain management is often of poor quality and inconsistent from shift to shift.<sup>33</sup> Adopting an objective pain assessment method greatly enhances the quality of pain management in NICUs and elsewhere by avoiding untreated pain or excessive analgesia. Pain assessment methods should be designed to reduce the nursing workload; the side effects of underdosing or overdosing analgesics; the clinical practice variability within and across different NICUs; and complications like tolerance, withdrawal, or delayed recovery from analgesia/sedation.<sup>34–36</sup>

### ***Pain Assessment Methods***

Currently available methods for neonatal pain assessment may be unidimensional (one parameter) or multidimensional (physiologic, behavioral, or other parameters).<sup>31,37,38</sup> Several multidimensional assessment tools with demonstrated validity, reliability, and clinical utility are used in the NICU.<sup>15,39,40</sup> These tools are based on indicators readily assessed at the bedside, such as changes in heart rate, respiratory pattern, blood pressure, or oxygen saturation. Behavioral responses include crying, changes in facial expressions, and body movements.<sup>41,42</sup> For example, total facial activity and a cluster of specific facial findings (brow bulge, eye squeeze, nasolabial furrow, open mouth) were associated with acute and postoperative pain.<sup>43,44</sup>

The tools most commonly used in the NICU for acute pain assessment include the Premature Infant Pain Profile (PIPP),<sup>39</sup> Neonatal Pain Agitation and Sedation Scale (N-PASS),<sup>45,46</sup> Neonatal Infant Pain Scale (NIPS),<sup>47</sup> and the CRIES scale (Crying, Requires Oxygen Saturation, Increased Vital Signs, Expression, Sleeplessness).<sup>15</sup> Premature infants, the most likely group to undergo painful procedures, are less likely to consistently demonstrate the responses to pain selected by these assessment tools.<sup>41,48–50</sup> These scales have been evaluated for acute pain and some for postoperative pain, but none of these methods assess persistent or chronic pain in neonates.<sup>32,51</sup> Two multicenter studies reported a wide range of pain assessment methods used in NICUs: 12 sites evaluated by the 2002 Neonatal Intensive Care Quality Improvement Collaborative used 5 different assessment tools,<sup>28</sup> whereas 10 sites in the Child Health Accountability Initiative used 8 different assessment tools.<sup>24</sup>

*Limitations* of these pain assessment methods include:

- Most methods were developed from and validated for neonates undergoing acute pain (eg, venipuncture, heelstick).
- Many of the signs used in these assessment tools require subjective evaluations by observers. As a result, there is significant interobserver variability in the evaluation of behavioral responses.<sup>52</sup>
- Some parameters like heart rate variability or palmar skin conductance require specialized equipment that is not routinely available at the bedside.
- Other measures like salivary cortisol or other biomarkers are not available in real time to be clinically useful.
- Behavioral pain responses may be altered in neurologically impaired neonates and absent in those who receive neuromuscular blockade.

Methods for the assessment of persistent or prolonged pain in neonates (for major surgery, osteomyelitis, necrotizing enterocolitis) have not been developed or validated.<sup>32,51,53</sup> During episodes of persistent pain, newborns exhibit a passive state, with limited or no body movements, expressionless facies, reduced physiologic variability, and decreased oxygen consumption. Also, behavioral responses depend on

the subjective judgments of rotating care providers,<sup>32</sup> leading to significant interobserver variability. Clinicians must also recognize potentially important relationships between the infant's pain response and the sensitivity and receptivity of the infant's care providers.<sup>54</sup>

Current efforts to improve the accuracy of pain assessment tools include the use of neuroimaging and neurophysiologic techniques that measure brain activity in order to validate neonatal pain scales.<sup>32,55</sup> Their goal is to provide clinicians at the bedside reliable and accurate methods to detect pain and quantify its intensity.

## MANAGEMENT OF PAIN

### *Nonpharmacologic Approaches*

---

Nonpharmacologic approaches to pain relief are underappreciated, underutilized, and understudied.<sup>56</sup> These methods of pain relief have demonstrated effectiveness in NICU care in certain situations, and modern NICUs should use these methods when appropriate. Although opinions differ on the use of complementary and alternative medicine, up to half of the population of the developed countries use this form of therapy<sup>57</sup>; 13.7% of the US population seeks advice from alternative therapists and doctors annually.<sup>58</sup> Opinions range from "Research on alternative medicine is frequently of low quality and methodologically flawed, which might cause these results to be exaggerated" (Report on Complementary & Alternative Medicine in the United States, Institute of Medicine, 2005) and "clothe naked quackery and legitimise pseudoscience"<sup>59</sup> to being "less dangerous and as effective as pharmacologic therapy."<sup>60</sup>

#### *Reduction of painful events*

Perhaps the most effective method to eliminate neonatal pain is to reduce the number of procedures performed and episodes of patient handling. NICUs and newborn nurseries should develop policies that limit handling and invasive procedures, without compromising the care of the infants. With forethought and planning, clustered care can reduce the number of bedside disruptions; but it may increase pain responses.<sup>61,62</sup> Other approaches include

1. Decrease bedside disruptions by timing routine medical interventions (daily physical examinations) with other care procedures (diaper change or suctioning).
2. Anticipate laboratory testing to minimize the frequency of blood sampling.
3. Use handheld devices that can perform several analyses (pH, PaO<sub>2</sub>, PaCO<sub>2</sub>, electrolytes, calcium, bilirubin, lactate) from a single small blood sample, thereby reducing the number of heelsticks required for laboratory testing.
4. Place peripheral arterial or central venous catheters in patients who need more than 3 to 4 heelsticks per day. These procedures should be performed with adequate analgesia.
5. If clinically appropriate, use noninvasive monitoring, such as transcutaneous PaO<sub>2</sub>, PaCO<sub>2</sub>, oxygen saturations, glucose or bilirubin levels, or near infrared spectroscopy, to avoid the need for blood sampling.
6. Consider the use of noninvasive therapeutic approaches for providing analgesia in newborns (eg, transdermal patches, iontophoresis, compressed air injectors).

#### *Kangaroo care and facilitated tucking*

Kangaroo care (KC) is defined as skin-to-skin contact, most commonly instituted shortly after birth. KC has been used in developing countries for warmth and bonding, while decreasing morbidity and mortality, especially in preterm neonates.<sup>63</sup> In developed countries, many health care workers are unaware of the benefits of KC. During heelsticks, KC decreases crying time, improves pain scores, and decreases

stress in preterm neonates, similar to facilitated tucking.<sup>64,65</sup> The mechanism of action of KC is unclear. Possibilities include the ability of the newborn to hear the maternal heartbeat, less maternal stress, and enhanced self-regulation.<sup>66,67</sup> KC is safe in preterm neonates who are stable and weigh more than 1000 g. However, 2 hours of KC daily was not effective in reducing stress levels in preterm neonates as measured by salivary cortisol.<sup>68</sup> During holding, KC decreases adverse cardiorespiratory events.<sup>69</sup>

Facilitated tucking is defined as placing a hand on the baby's hands or feet and positioning the baby to provide support yet allow them to control their own body movements and is similar to providing KC. It has been used to alleviate pain during endotracheal suctioning and heelsticks.<sup>70</sup> However, it may not be as effective as oral sucrose for repeated painful procedures.<sup>71</sup>

### ***Non-nutritive sucking, sucrose and other sweeteners***

Pain relief has been provided by non-nutritive sucking, with and without sucrose, glucose, and breast feeding. Non-nutritive sucking and sweeteners seem to work by increasing endogenous endorphins, as naloxone seems to blunt the response; however, the mechanism is not completely understood.<sup>72</sup> Sweeteners seem to augment the antinociceptive response to pain compared with non-nutritive sucking.<sup>73</sup> Both sucrose and glucose enhance its effectiveness; they both decrease crying time and improve pain scores after acute mild pain, such as from heelsticks.<sup>74,75</sup> A recent meta-analysis revealed that glucose is an acceptable alternative to sucrose, decreasing PIPP scores and crying times associated with venipuncture and heelstick.<sup>76</sup> Sucrose is efficacious in reducing the pain from single events, such as retinopathy of prematurity screening,<sup>77</sup> oral gastric tube insertion,<sup>78</sup> and heelsticks.<sup>71</sup> However, sucrose is controversial when given repeatedly, possibly leading to adverse long-term outcomes.<sup>79</sup> Optimal dosing of sucrose is not known, and a recent Cochrane Review raised concerns about repeated dosing or use in extremely preterm or ill neonates.<sup>80</sup> Breast feeding, especially when accompanied by skin-to-skin contact, is more efficacious than either alone in reducing pain associated with heelstick; however, there is a limited number of studies in the preterm population.<sup>81</sup>

### ***Massage therapy***

Massage therapy involves hands-on and skin-to-skin manipulation of the soft tissue that includes gentle effleurage (rhythmic, gliding strokes conforming to the contours of the body), light petrissage (lifting, rolling, kneading strokes done slowly), and compression (light compression of selected areas) and nerve stroke (very light brushing of the skin). It is thought to work by enhancing vagal activity, modulating insulin and insulin-like growth factor 1, as well as decreasing levels of cortisol and epinephrine.<sup>82</sup> Massage therapy has demonstrated effectiveness in randomized trials. Massage decreased NIPS scores in 13 infants receiving heelsticks preceded by a 2 minute-massage in the ipsilateral leg,<sup>83</sup> increased weight gain via vagal stimulation,<sup>84</sup> and improved neurodevelopmental outcomes in very low birth weight neonates.<sup>85</sup> It does not induce sleep in stable preterm neonates, limiting its usefulness as a sedative (Yates CC, personal communication, 2014).

### ***Acupuncture***

Acupuncture is the stimulation of acupuncture points by mechanical or electrical means<sup>86</sup> to elicit pain relief. It works by stimulation of the endorphin or non-opioidergic analgesic systems. Despite its use in China for thousands of years and its frequent use by patients in developed countries, it has not gained widespread acceptance in conventional Western medicine.

In conclusion, nonpharmacologic therapies are safe and effective for minor pain and as an adjunct for moderate or severe pain. KC is effective for pain relief during the holding period; it is safe in clinically stable term and preterm neonates weighing more than 1000 g and has beneficial effects on growth, mother-infant bonding, and long-term neurodevelopmental outcomes. Facilitated tucking can provide some pain relief for endotracheal suctioning but is not as effective as sucrose for skin-breaking procedures. Sucrose, glucose, breast milk, and other sweeteners with or without non-nutritive sucking have specific analgesic effects for most skin-breaking procedures, although the safety of repeated use has not been established. Massage therapy decreases pain scores and promotes weight gain in preterm neonates, whereas acupuncture has been inadequately studied in neonates. The use of non-pharmacologic therapies is often recommended as the first step in neonatal pain management, particularly because of their favorable side-effect profile, their ability to diminish acute pain from invasive or noninvasive procedures, and their beneficial long-term effects as compared with the systemic analgesics.

### **Local Anesthetics**

---

#### ***Lidocaine infiltration***

Lidocaine inhibits axonal transmission by blocking sodium ion channels. Lidocaine infiltration is commonly used for various penile blocks for circumcision. In this circumstance, its use has demonstrated effectiveness in decreasing the pain response to immunizations as long as 4 months after circumcision compared with neonates who received placebo.<sup>87</sup> Compared with a dorsal penile root block or eutectic mixture of local anesthetics (lidocaine and prilocaine combination [Eutectic Mixture of Local Anesthetic (EMLA)]) cream, the ring block has been shown to be the most effective means of pain relief for circumcision.<sup>88</sup>

#### ***Topical anesthetics***

Topical anesthetics are effective for certain types of procedural pain, such as venous cannulation,<sup>89</sup> lumbar puncture,<sup>90</sup> or venipuncture.<sup>91</sup> One study reported combining sucrose with topical analgesia, which resulted in lower Douleur Aigue Nouveau-ne (DAN) scores.<sup>92</sup> Another study demonstrated increased success with venipuncture in young infants and children if the cream was left in place for 2 hours or more.<sup>93</sup> EMLA cream was studied in preterm neonates subjected to venipuncture. N-PASS scores were significantly lower in the treated group compared with placebo, leading the investigators to recommend this method of analgesia.<sup>94</sup> Tetracaine is also used topically, with varying success. When combined with sucrose, one study found no benefit of this formulation,<sup>95</sup> whereas another review found similar efficacy but with a more rapid onset of action as compared with EMLA cream, making it attractive for clinical use.<sup>96</sup>

Complications of the topical creams include methemoglobinemia and transient skin rashes.<sup>97</sup> Concerns for methemoglobinemia are exaggerated in preterm neonates because of a thinner epidermis, high dermal permeability, and limited circulating antioxidants. However, when used properly (as recommended by the Food and Drug Administration), very few neonates develop toxic methemoglobinemia even after repeated EMLA use.<sup>98-101</sup> Newer topical anesthetics include 4% tetracaine and 4% liposomal lidocaine, with a shorter onset of action; but they are not more effective.

Unfortunately, topical anesthetics have not been effective in providing pain relief for heelsticks, one of the most common skin-breaking procedures,<sup>102</sup> although they may reduce hyperalgesia following the tissue injury associated with heelsticks.<sup>103</sup>

## Opioid Therapy

Opioids provide the most effective therapy for moderate to severe pain in patients of all ages. They produce both analgesia and sedation, have a wide therapeutic window, and also attenuate the physiologic stress responses of neonates. Morphine and fentanyl are the most commonly used opioids, although some NICUs report the use of more potent (eg, sufentanil),<sup>104</sup> shorter-acting (eg, alfentanil,<sup>105,106</sup> remifentanil<sup>107,108</sup>), or mixed opioids (eg, tramadol<sup>109</sup>).

### Morphine

Morphine is the most commonly used opioid for neonatal analgesia, often used as a continuous infusion in ventilated or postoperative infants or intermittently to reduce the acute pain associated with invasive procedures. Its effectiveness and safety for these indications has not been established but remains under active investigation.

Morphine improves ventilator synchrony in ventilated neonates,<sup>110,111</sup> although recent multicenter trials have questioned the benefit of routine morphine infusions in ventilated preterm infants. The Neurologic Outcomes and Pre-emptive Analgesia in Neonates (NEOPAIN) multicenter trial evaluated 898 ventilated preterm infants (23–32 weeks' gestation) randomly assigned to morphine or placebo infusions.<sup>112</sup> Open-label morphine was given for additional analgesia based on the clinical judgment of clinicians in each of the NICUs. There were no differences in the rates of mortality, severe intraventricular hemorrhage (IVH), or periventricular leukomalacia (PVL) between the two groups, even though neonates in the morphine group seemed to have lower PIPP scores and smaller increases in heart rate and respiratory rate.<sup>112</sup> These differences were small but reached statistical significance because of the large sample size. Infants treated with morphine were more likely to develop hypotension,<sup>113</sup> required a longer duration of mechanical ventilation, and took longer to tolerate enteral feeds.<sup>112,114</sup>

Another trial that randomized 150 ventilated term and preterm neonates in 2 Dutch centers found no differences in the analgesic effects of morphine versus placebo using multiple measures of pain assessment. A lower incidence of IVH occurred in the morphine group, but no differences in poor neurologic outcome occurred between the two groups.<sup>115</sup> A systematic review selected 13 randomized controlled trials (RCTs) on the use of opioids in ventilated infants. Pooled data from 4 studies using PIPP scores showed reduced pain in the patients who received morphine versus placebo (weighted mean difference  $-1.71$ , 95% confidence interval  $-3.18$  to  $-0.24$ ).<sup>116</sup> Additional analyses demonstrated no differences in mortality rates (5 RCTs), duration of mechanical ventilation (10 RCTs), or neurodevelopment outcomes evaluated at 5 to 6 years of age (2 RCTs) and no differences in secondary outcomes (rates of necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), IVH, PVL, and hypotension), except that preterm infants in the morphine groups took longer to tolerate full enteral feeds.<sup>116</sup>

Morphine analgesia is associated with significant side effects in preterm infants, but it may or may not alter their long-term cognitive or behavioral outcomes.<sup>17,18,116–119</sup> A retrospective study of 52 term neonates with hypoxic-ischemic insults following birth asphyxia showed less brain injury on MRI and improved neurodevelopmental outcomes in infants who received morphine in the first week after birth compared with those who did not receive opioid therapy.<sup>120</sup> The routine use of morphine infusions is not recommended for ventilated preterm neonates but may be beneficial for term neonates following birth asphyxia.

Morphine analgesia may not be associated with the same risk profile in ventilated term infants but may still increase the duration of ventilation. A retrospective study

of 62 ventilated term newborns found that postoperative morphine infusions prolonged the need for mechanical ventilation but was not associated with apnea, hypotension, or other complications.<sup>121</sup> A series of RCTs comparing intermittent versus continuous morphine infusions found that morphine is safe and effective for postoperative pain in term neonates and older infants.<sup>122–128</sup> Currently, however, there are no RCTs that have investigated the safety and efficacy of postoperative morphine analgesia in preterm neonates.

The analgesic effects of morphine in reducing acute procedural pain are controversial.<sup>115,129,130</sup> During CVL placement, one RCT found that ventilated neonates receiving morphine alone and morphine plus tetracaine had lower pain scores than the no treatment or tetracaine alone groups. However, patients who received morphine required greater ventilatory support in the 12 hours following the procedure.<sup>130</sup> In contrast, the NEOPAIN and Dutch morphine trials evaluated the responses to heelstick or tracheal suctioning, respectively, in preterm infants randomized to continuous morphine or placebo infusions and found no difference in pain scores between the two groups.<sup>115,129,131</sup> Morphine pharmacodynamics studies in ventilated preterm neonates also found no relationship between plasma morphine levels and responses to tracheal suctioning.<sup>131,132</sup> Of note, the preparation of morphine infusions in the NICU from regular morphine vials involves the manual dilution of small volumes, leading to significant inaccuracies in the concentrations delivered to neonates.<sup>133</sup>

### **Fentanyl**

As a highly lipophilic drug, fentanyl provides rapid analgesia with minimal hemodynamic effects in term and preterm newborns, although its popular use is not supported with evidence from large multicenter RCTs. Smaller trials reported that fentanyl reduces stress hormone levels, episodes of hypoxia, and behavioral stress scores in ventilated infants as compared with placebo controls.<sup>134–136</sup> Although infants who received fentanyl required greater ventilatory support, no differences occurred in clinical outcomes between the fentanyl- and placebo-treated groups.<sup>135,136</sup> Another RCT reported that behavioral pain scores and cytokine release following heel sticks were reduced to a greater extent with fentanyl (1–2 mcg/kg) as compared with facilitated tucking.<sup>137</sup>

Fentanyl<sup>138–141</sup> or its shorter-acting derivatives (eg, alfentanil,<sup>105</sup> remifentanil<sup>142,143</sup>) are often used for analgesia before procedures in preterm and term newborns. A randomized trial in 20 preterm newborns found that overall intubating conditions were significantly improved in those receiving remifentanil versus morphine. However, no complications occurred following either intravenous (IV) morphine or remifentanil.<sup>143</sup>

Although the AAP/CPS guidelines do not recommend the routine use of continuous fentanyl infusions in ventilated preterm neonates, this occurs frequently in many NICUs.<sup>144,145</sup> In a multicenter RCT in 131 mechanically ventilated preterm infants (23–32 weeks' gestation), fentanyl infusions reduced acute pain (PIPP) scores; no differences occurred in the prolonged pain Échelle Douleur Inconfort Nouveau-Né (EDIN) scores between the two groups, although fewer neonates showed EDIN scores greater than 6 in the fentanyl (6.8%) versus placebo groups (10.6%).<sup>146</sup> Those receiving fentanyl infusions had a longer duration of mechanical ventilation and delayed passage of meconium.<sup>146</sup>

Fentanyl analgesia is associated with less sedative or hypotensive effects, reduced effects on gastrointestinal motility or urinary retention, but greater opioid tolerance and withdrawal as compared with morphine.<sup>146–149</sup> A single-center RCT compared infusions of fentanyl (1.5 mcg/kg/h) versus morphine (20 mcg/kg/h) in 163 ventilated neonates and reported similar pain scores, catecholamine responses, and vital signs in both groups. There were no adverse respiratory effects or difficulties in weaning



from ventilation in either group, but decreased beta-endorphin levels and gastrointestinal dysmotility occurred in the fentanyl group.<sup>149</sup> In another double-blind RCT, single doses of fentanyl (3 mcg/kg) reduced physiologic and behavioral indicators of pain, improved postoperative comfort scores, and increased growth hormone levels in ventilated preterm neonates.<sup>134</sup> Among postoperative preterm infants, fentanyl and tramadol provided equally effective analgesia, with no differences between the two groups for the duration of mechanical ventilation or the time to reach enteral feeds.<sup>109</sup>

Fentanyl should be used when a rapidly acting opioid is required for analgesia in a controlled setting, where any associated side effects (bradycardia, hypotension, laryngospasm, and chest wall rigidity<sup>150</sup>) can be addressed rapidly and adequately. Other indications include fentanyl analgesia for postoperative pain (following cardiac surgery)<sup>151,152</sup> or for patients with pulmonary hypertension (primary or secondary).<sup>153,154</sup> A single-center RCT using continuous fentanyl infusions following cardiac surgery found significant differences in postoperative complications and mortality compared with intermittent doses of morphine and diazepam,<sup>13</sup> although it is unclear whether these clinical outcomes were related to anesthetic management or postoperative analgesia. Further studies of fentanyl analgesia for ventilated preterm neonates, and for term and preterm neonates exposed to postoperative pain, are required to evaluate its safety and efficacy in these patients.

Based on current evidence and clinical experience, the routine use of fentanyl infusions in ventilated preterm infants cannot be recommended at this time,<sup>116</sup> except for neonates undergoing tracheal intubation, central line placement, or surgery. Morphine analgesia may be used in ventilated term neonates following surgery or birth asphyxia or in those requiring moderately invasive procedures, such as central venous catheterization, tracheal intubation, or chest tube placement. Exercise extreme caution if using opioid analgesia for preterm neonates at 22 to 26 weeks' gestation or in those with preexisting hypotension because of the increased risk for adverse events, including hypotension, bradycardia, severe IVH, impaired gut motility, and worse neurodevelopmental outcomes.<sup>113</sup>

### ***Remifentanyl, alfentanil, sufentanil***

Remifentanyl has a chemical structure similar to that of fentanyl but has twice its analgesic potency with an ultrashort duration of action (3–15 minutes). It is metabolized by plasma esterases in erythrocytes and tissue fluids, thus its excretion is independent of liver and renal function.<sup>155</sup> Remifentanyl is used for pain relief during brief procedures, such as central line placement<sup>142</sup> or tracheal intubation.<sup>143</sup> Alfentanil is more potent than morphine but has approximately one-third the potency of fentanyl and has a short duration of action (20–30 minutes).<sup>105,156</sup> These drugs have been used successfully for tracheal intubation and other brief invasive procedures in neonates, but detailed safety and efficacy data are lacking.<sup>157</sup>

For a summary of the opiates see [Table 1](#).

## ***Nonopioid Therapies***

---

### ***Benzodiazepines***

Benzodiazepines activate gamma aminobutyric acid A (GABA<sub>A</sub>) receptors<sup>158</sup> and are commonly used in NICUs, but they have no analgesic effects. These drugs provide sedation and muscle relaxation, making them useful for noninvasive procedures, such as imaging studies and as an adjunct for motion control in invasive procedures. Their adverse effects include myoclonic jerking, excessive sedation, respiratory depression, and occasional hypotension.

<b>Drug</b>	<b>Advantages</b>	<b>Disadvantages</b>
Morphine	Potent pain relief Better ventilator synchrony Sedation Hypnosis Muscle relaxation Inexpensive	Respiratory depression Arterial hypotension Constipation, nausea Urinary retention Central nervous system depression Tolerance, dependence Long-term outcomes not studied Prolonged ventilator use
Fentanyl	Fast acting Less hypotension	Respiratory depression Short half-life Quick tolerance and dependence Chest wall rigidity Inadequately studied
Remifentanyl	Fast acting Degraded in the plasma Unaffected by liver metabolism	—

**Midazolam** Midazolam is the most commonly used benzodiazepine in the NICU, although concerns regarding its usage have been raised. Although there are relatively few studies to support the use of midazolam in neonates, it is common practice to use this drug for mechanical ventilation or procedural pain.<sup>159</sup> One recent review found no apparent clinical benefit of midazolam compared with opiates in mechanically ventilated neonates.<sup>160</sup> There are some concerns regarding the use of midazolam in neonates. One study reported an increased incidence of adverse short-term effects (intraventricular hemorrhage, periventricular leukomalacia, or death) and a longer hospital stay associated with midazolam compared with morphine.<sup>161</sup> Midazolam has also been associated with benzyl alcohol exposure.<sup>162</sup> A recent Cochrane Review found insufficient data to promote the use of IV midazolam as a sedative in the NICU, in addition to “concerns about the safety of midazolam in neonates.”<sup>163</sup> It is also used for noninvasive procedures, such as computed tomography (CT) scans<sup>164</sup> and less invasive procedural sedation.<sup>165</sup> One recent study found a significant effect of midazolam on pain scores after surgery.<sup>166</sup> There have been no long-term studies describing a benefit or harm with midazolam. In summary, midazolam seems to provide sedative effects in mechanically ventilated neonates; but it should be used with caution because of reported adverse effects, particularly when used alone. The decreased number of GABA<sub>A</sub> receptors in neonates compared with adults may contribute to the neonates’ risk of neuroexcitability and myoclonic activity that resembles and, in some cases, may progress to seizure activity.<sup>167</sup>

A starting dose of 100 mcg/kg with a maintenance dosage of 50 to 100 mcg/kg/h can be used in neonates to provide sedation.<sup>168</sup> Oral midazolam is also effective, with 50% bioavailability compared with the IV preparation.<sup>169,170</sup> Finally, intranasal midazolam was effective for fundoscopic examinations in older children; but this mode of delivery has not been tested in neonates.<sup>171</sup> Metabolism of these drugs occurs through glucuronidation in the liver; there is potential for decreased bilirubin metabolism, especially in asphyxiated or preterm newborns. Its half-life is only 30 to 60 minutes, which is prolonged in preterm and sick neonates. Recent pharmacokinetic data reveal a significant effect of maturation and body weight on the clearance of midazolam, which has elucidated the ability to predict levels in this age group.<sup>172</sup>

However, it adheres to the tubing in patients on extracorporeal membrane oxygenation (ECMO), increasing their dosing requirements by 50%.<sup>173</sup>

**Lorazepam** Lorazepam has also been used in the NICU, albeit not as routinely as midazolam. It is a longer-acting drug than midazolam, with a duration of action 6 to 12 hours, so it does not have to be given as an infusion. It has been used successfully for seizure control in neonates who are refractory to phenobarbital and phenytoin despite its potential for neuronal toxicity.<sup>174</sup> Its use has also been associated with propylene glycol exposure.<sup>162</sup> For a summary of the benzodiazepines see **Table 2**.

#### **Other sedatives**

**Phenobarbital** Phenobarbital is usually considered as the drug of choice for seizure control. There is sparse evidence for the antinociceptive effects of phenobarbital in animals,<sup>175</sup> but it has no significant analgesic effects in humans. It was used in conjunction with opioids for sedation,<sup>161</sup> although there is little recent evidence that it is effective. Classically, it has been used for neonatal abstinence syndrome; but recent work by Ebner and others<sup>176</sup> has demonstrated that opiates shorten the time required for treatment. However, because of its anticonvulsant effects, phenobarbital is an attractive agent for patients with seizures.

**Propofol** Propofol has become popular as an anesthetic agent for young children, but it has not been studied extensively in neonates.<sup>177</sup> One study compared propofol with morphine, atropine, and suxamethonium for intubation and found that propofol led to shorter intubation times, higher oxygen saturations, and less trauma than the combination regimen in neonates; but these effects were not significantly different.<sup>178,179</sup> However, propofol should be used with caution in young infants because its clearance and potential for neurotoxicity are inversely related to neonatal and postmenstrual age. There is significant interindividual variability in the pharmacokinetics of propofol in preterm neonates<sup>180</sup>; its use can lead to severe hypotension, with transient decreases in heart rate and oxygen saturations.<sup>181</sup>

<b>Table 2 Benzodiazepines</b>		
<b>Drug</b>	<b>Advantages</b>	<b>Disadvantages</b>
Benzodiazepines	Better ventilator synchrony Antianxiety Sedation Hypnosis Muscle relaxation Amnesia Anticonvulsant	No pain relief Arterial hypotension Respiratory depression Constipation, nausea Urinary retention Myoclonus Seizures Central nervous system depression Tolerance, dependence Alters bilirubin metabolism Propylene glycol and benzyl alcohol exposure
Midazolam	Most studied benzodiazepine Quickly metabolized	Short acting Benzyl alcohol exposure
Lorazepam	Longer acting Better anticonvulsant	More myoclonus reported Propylene glycol exposure
Diazepam	—	Not recommended in the neonate

**Ketamine** Ketamine is a dissociative anesthetic that provides analgesia, amnesia, and sedation. Although ketamine has been used extensively in older children, there have been limited studies in neonates. Ketamine increases blood pressure and heart rate, increases the respiratory drive, and leads to bronchodilation.<sup>182</sup> Because ketamine does not affect cerebral blood flow significantly, it is a good choice for unstable, hypotensive neonates requiring procedures such as intubation or ECMO cannulation.<sup>183</sup> In the authors' laboratory, ketamine decreased neuronal cell death in the presence of repetitive pain in immature rodents, which would also make it attractive for preterm neonates,<sup>184</sup> although no significant differences occurred in human studies. The dose for effective management of the pain caused by endotracheal suctioning in ventilated neonates was 2 mg/kg in one Finnish study.<sup>185</sup> Despite these theoretic advantages, ketamine is a potent anesthetic with minimal study in neonates. Therefore, it should only be used for invasive procedures.

**Dexmedetomidine** Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that provides potent sedative and analgesic effects while causing minimal respiratory depression. Although dexmedetomidine is approved for sedation of patients undergoing surgical or other procedures, the clinical experience using this drug in neonates is limited. Ongoing research on its safety, dosing, and efficacy is being conducted in preterm and term infants, particularly following cardiac surgery.<sup>186–192</sup> Therefore, the routine use of this drug in ventilated neonates is not recommended until sufficient data demonstrating its safety and efficacy and its pharmacokinetics and pharmacodynamics have been published. Clinicians using this drug should note that the plasma levels producing sedation (0.4–0.8 mcg/L) are lower than those producing analgesia (0.6–1.25 µg/L), at least in older children,<sup>193–196</sup> and that it may cause seizures,<sup>197</sup> bradycardia,<sup>198,199</sup> and hypothermia<sup>198</sup> in neonates. However, it seems to be useful for radiological procedures<sup>200–202</sup> and supraventricular tachyarrhythmias<sup>192,203</sup> in infants and children.

**Chloral hydrate** Chloral hydrate is not available in the United States but is commonly used in European NICUs when sedation is required without analgesia. It is commonly used for radiological procedures, electroencephalography, echocardiography, and dental procedures in older patients. It is converted to trichloroethanol, which is also metabolically active.<sup>204</sup> A recent retrospective review found an increased incidence of apnea and desaturation in term neonates less than 1 month and in preterm neonates less than 60 weeks postconceptual age who were undergoing MRI.<sup>205</sup> One study evaluated the combination of chloral hydrate and acetaminophen in ophthalmologic surgery for retinopathy of prematurity, comparing it with IV opioid analgesia. Although there was a general reduction in pain scores, some of the infants in this study had very high pain scores with the chloral hydrate preparation, making this combination questionable at best.<sup>206</sup> In summary, this drug should be used for sedation without analgesia and with caution in preterm and young term neonates.

#### **Acetaminophen (Paracetamol)**

Acetaminophen inhibits the cyclooxygenase-2 (COX-2) enzymes in the brain; it has been well studied in newborns.<sup>207</sup> It is frequently used in conjunction with other types of pain relief to decrease opioid use, especially for postsurgical pain.<sup>208</sup> IV acetaminophen decreased the amount of opioids needed after surgery and is particularly useful for routine postsurgical care with opioid-sparing effects.<sup>209</sup> The main toxicity of this drug is liver damage; but when given in appropriate doses, it is safe and effective. One of the main concerns surrounding acetaminophen is drug overdosage, which

can lead to significant liver toxicity.<sup>210</sup> Acetaminophen has also been used for procedural pain, such as immunizations or circumcision.<sup>211</sup>

In infants, oral, rectal, and IV formulations of acetaminophen have minimal adverse effects. In contrast to its use in older children or adults, acetaminophen rarely causes hepatic or renal toxicity in newborns.<sup>211–215</sup> In addition, IV acetaminophen does not induce hypothermia in neonates.<sup>216</sup> The prodrug is available as another IV formulation, marketed in European and other countries as propacetamol, although it causes more frequent side effects.<sup>217–219</sup>

In both preterm and term infants, the clearance of acetaminophen is slower than older children, so oral/rectal dosing is required less frequently.<sup>218,220–226</sup> Single *oral* doses of 10 to 15 mg/kg may be given every 6 to 8 hours, and 20 to 25 mg/kg can be given *rectally* at the same time intervals. These doses were primarily based on antipyretic dose-response studies and may not apply for pain control. Although limited data are available for *IV* acetaminophen in neonates, a pharmacokinetic analysis in 158 infants suggests a loading dose of 20 mg/kg and maintenance dosages of 10 mg/kg every 6 hours for infants at 32 to 44 weeks' postmenstrual age.<sup>226</sup> However, maintenance dosing for Extremely Low Gestational Age Neonates (ELGANs) is controversial and may be less than or equal to 7.5 mg/kg every 6 to 8 hours for neonates between 23 and 32 weeks' postmenstrual age.<sup>209,226</sup> The recommended total daily doses based on postmenstrual age are

- 24 to 30 weeks' gestation: 20 to 30 mg/kg/d
- 31 to 36 weeks' gestation: 35 to 50 mg/kg/d
- 37 to 42 weeks' gestation: 50 to 60 mg/kg/d
- 1 to 3 months' postnatal: 60 to 75 mg/kg/d

Wider use of acetaminophen as an analgesic will allow clearer definition of the adverse effects and safety profile of this useful drug in the neonatal population.<sup>34</sup>

### **Nonsteroidal antiinflammatory drugs**

Nonsteroidal antiinflammatory drugs (NSAIDs) are used extensively for pain relief in children and adults, but drugs like indomethacin<sup>227,228</sup> and ibuprofen<sup>229–231</sup> are mainly used for patent ductus arteriosus closure in neonates. They act by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2) responsible for converting arachidonic acid into prostaglandins, thus producing their analgesic, antipyretic, and antiinflammatory effects.<sup>232</sup> There are little data on the analgesic effects of NSAIDs in neonates. Concern over the side effects of renal dysfunction, platelet adhesiveness, and pulmonary hypertension have limited their study to this indication.<sup>233</sup> However, ibuprofen has demonstrated beneficial effects on cerebral circulation in human studies as well as beneficial effects on the development of chronic lung disease in baboon experiments,<sup>234</sup> making it potentially useful as an analgesic in preterm neonates.

## **IMPLEMENTING PAIN MANAGEMENT IN THE NEONATAL INTENSIVE CARE UNIT: A QUALITY IMPROVEMENT APPROACH**

Pain in modern-day NICUs is inadequately treated, despite the overwhelming evidence depicting the adverse consequences of unrelieved pain/stress. Carbajal and colleagues<sup>22</sup> found that preterm neonates experienced 10 to 14 painful procedures daily, most of which (80%) were not preceded by specific analgesia. Numerous other NICUs have noted similar findings.<sup>235–237</sup> Even more concerning is the potential that chronic pain may be ignored, especially in mechanically ventilated neonates.<sup>238</sup> Barriers include inadequate ability to assess prolonged neonatal pain, lack of knowledge of therapeutic effectiveness, and exaggerated concerns over analgesic side effects.

Further, the inherent difficulties in conducting human pain research in neonates require an ethical approach that will leave most studies seriously flawed.

### ***Developing Neonatal Intensive Care Unit: Specific Guidelines***

---

A suggested approach to evidence-based recommendations for the treatment of neonatal pain includes the following<sup>239</sup>:

1. Recognition of neonatal pain as a valid concern
2. Recognition of acute procedural and chronic neonatal pain in need of treatment
3. Regular use of a validated assessment tool for neonatal pain
4. Educational resources for care givers and parents in the NICU
5. Protocolized stepwise treatment plan for the procedures and conditions encountered in the NICU using nonpharmacologic and pharmacologic approaches to treatment
6. Continued auditing to ascertain appropriate treatment of neonatal pain
7. Well-planned program of coordination, facilitation, and using local champions and project teams

Stevens and colleagues<sup>240</sup> identified 3 overarching themes that captured influences on optimal pain practices in the NICU:

1. A culture of collaboration and support among all health care providers *and patients' families*
2. Threats to autonomous decision making, such as autocratic leadership and hierarchical relationships
3. Complexities in care delivery, related to the complexities of the patients as well as the system of care

The authors recommend a quality-improvement approach, involving all members of the health care team and families to discuss the causes, prevention, and evidence-based treatment of pain. Education must be provided with continual assessment, which should be documented consistently according to the Joint Commission's requirements. By using this approach, the authors were able to decrease the number of painful procedures to less than 2 per day in neonates between 27 and 32 weeks' postconceptual age.<sup>68</sup>

### ***Analgesia for Invasive Procedures***

---

Analgesic approaches for specific procedures are listed in [Table 3](#).

#### ***Postoperative Analgesia***

---

Opiates remain the mainstay of postoperative pain relief. However, because of the concerns surrounding prolonged opiate therapy, many centers are using IV acetaminophen to augment opiate therapy. Its use has decreased the amount of opiates received by postoperative patients.<sup>209</sup>

#### ***Analgesia for Mechanical Ventilation***

---

Mechanical ventilation is one of the most common sources of chronic pain in modern NICUs. Newer, more effective surfactants, the use of prenatal steroids, and improved nutrition has brought about a new generation of survivors, many of whom require several months of assisted ventilation. Despite several well-conducted studies in ventilated preterm neonates, the ideal method of analgesia for assisted ventilation in preterm neonates is still unknown.<sup>112,115,161</sup> Thus, analgesia for mechanical ventilation is controversial for a variety of reasons.<sup>145</sup>

**Table 3**  
**Summary of procedures and recommendations for pain relief**

<b>Skin-Breaking Procedures<sup>a,b</sup></b>	<b>Proposed Interventions</b>	<b>Comments</b>
Heel stick	Use nonpharmacologic measures + mechanical lance, squeezing the heel is the most painful phase	Venipuncture is more efficient, less painful; local anesthetics, acetaminophen, heel warming do not reduce heel stick pain
Venipuncture	Nonpharmacologic measures, use topical local anesthetics	Requires less time & less resampling than heel stick
Arterial puncture	Nonpharmacologic measures, use topical and subcutaneous local anesthetics	More painful than venipuncture
IV cannulation	Nonpharmacologic measures, use topical local anesthetics	—
Central line placement	Nonpharmacologic measures, use topical local anesthetics, consider low-dose opioids or deep sedation based on clinical factors	Some centers prefer using general anesthesia
Finger stick	Nonpharmacologic measures and use mechanical device	Venipuncture is more efficient, less painful; local anesthetics, acetaminophen, or warming may not reduce finger stick pain
Subcutaneous injection	Avoid if possible, use nonpharmacologic measures and topical local anesthetics if procedure cannot be avoided	—
Intramuscular injection	Avoid if possible, use nonpharmacologic measures and topical local anesthetics if procedure cannot be avoided	—
Lumbar puncture	Nonpharmacologic measures and topical local anesthetic, lidocaine infiltration, careful positioning	Use IV analgesia/sedation, if patients are intubated and ventilated
Peripheral arterial line	Nonpharmacologic measures and topical local anesthetic, lidocaine infiltration, consider IV opioids	—
Circumcision	Nonpharmacologic measures and topical local anesthetic, lidocaine infiltration, IV/PO acetaminophen before and after procedure	Lidocaine infiltration for distal, ring, or dorsal penile nerve blocks (DPNB); liposomal lidocaine is more effective than DPNB
Suprapubic bladder aspiration	Nonpharmacologic measures and topical local anesthetic, lidocaine infiltration, consider IV fentanyl (0.5–1.0 mcg/kg)	—

*(continued on next page)*

**Table 3**  
*(continued)*

<b>Skin-Breaking Procedures<sup>a,b</sup></b>	<b>Proposed Interventions</b>	<b>Comments</b>
Arterial or venous cutdown	Nonpharmacologic measures and topical local anesthetic, lidocaine infiltration, IV fentanyl (1–2 mcg/kg), consider deep sedation	Most arterial or venous cutdowns can be avoided, consider referral to interventional radiology
Peripherally inserted central catheter (PICC)	Nonpharmacologic measures and topical local anesthetic, lidocaine infiltration, consider IV fentanyl (1 mcg/kg) or IV ketamine (1 mg/kg)	Some centers prefer using deep sedation or general anesthesia
ECMO Cannulation	Propofol 2–4 mg/kg, ketamine 1–2 mg/kg, fentanyl 1–3 mcg/kg, muscle relaxant as needed	—
Tracheal intubation (eg, for mechanical ventilation)	Give fentanyl (1 mcg/kg) or morphine (10–30 mcg/kg), with midazolam (50–100 mcg/kg), ketamine (1 mg/kg), use muscle relaxant only if experienced clinician, consider atropine	Superiority of one drug regimen over another has not been investigated
Gastric tube insertion	Nonpharmacologic measures, consider local anesthetic gel	Perform rapidly, use lubricant, avoid injury
Chest physiotherapy	Gentle positioning, fentanyl (1 mcg/kg) if a chest tube is present	Avoid areas of injured or inflamed skin, areas with indwelling drains or catheters
Removal of IV catheter	Solvent swab, consider nonpharmacologic measures	—
Wound treatment	Nonpharmacologic measures, use topical local anesthetics, consider low-dose opioids, or deep sedation based on extent of injury	See also “Dressing change”
Umbilical catheterization	Nonpharmacologic measures, IV acetaminophen (10 mg/kg), avoid sutures to the skin	Cord tissue is not innervated, but avoid injury to skin
Bladder compression	Consider nonpharmacologic measures or IV acetaminophen (10 mg/kg) if severe or prolonged	—
Tracheal extubation	Use solvent swab for tape, consider nonpharmacologic measures	—
Dressing change	Nonpharmacologic measures and topical local anesthetic, consider deep sedation if extensive	—

<sup>a</sup> Nonpharmacologic measures include pacifier, oral sucrose, swaddling, skin-to-skin contact with mother.

<sup>b</sup> The frequency of procedures can be reduced without sacrificing the quality of neonatal intensive care.



Mechanical ventilation leads to changes in neuroendocrine parameters, pain scores, and physiologic responses.<sup>134,241</sup> Assisted ventilation in neonates is presumed to be associated with chronic repetitive pain, which in turn is associated with adverse long-term sequelae.<sup>242</sup> Ventilated neonates treated with opiates have demonstrated improved ventilator synchrony<sup>243</sup>; improved pulmonary function; and decreased neuroendocrine responses, including cortisol, beta-endorphin, and catecholamines.<sup>145</sup> Reasons not to treat include the well-known adverse side effects of analgesics, especially the opiates, including hypotension from morphine<sup>113</sup>; chest wall rigidity from fentanyl and alfentanil<sup>105</sup>; and tolerance, dependence, and withdrawal from both opiates and benzodiazepines. Additionally, adverse effects, such as death and IVH, are not improved with preemptive treatment and may lead to adverse short-term effects.<sup>112</sup>

Chronic pain assessment is poorly validated and difficult to assess in this patient population, since most studies have only evaluated acute pain scores.<sup>238</sup> If patients are treated, opiates are the most common class of drugs, with morphine being the most well studied. Fentanyl may be advantageous in hypotensive and/or younger neonates because it has fewer cardiovascular effects. One recent study demonstrated improved acute pain scores with fentanyl, but time on the ventilator was prolonged compared with placebo.<sup>146</sup> Remifentanyl, especially when short-term intubation is needed,<sup>107</sup> and dexmedetomidine are promising agents; but neonatal data are limited.<sup>244,245</sup> The benzodiazepines, midazolam and lorazepam, have been used in ventilated neonates; but midazolam has been associated with adverse effects in one small study.<sup>161</sup> Significant gaps in our knowledge exist, especially in regard to long-term effects of treatment, or lack thereof, and in chronic pain assessment associated with assisted ventilation. Recent data from the NEOPAIN trial suggest improved long-term outcomes at school age from the morphine-treated group, with fewer children requiring special education (Hall RW, personal communication, 2013).

In conclusion

- If neonatal patients exhibit irritability on assisted ventilation, first optimize oxygenation and ventilation.
- Treat acute pain and stress episodically as needed.
- Do not treat ventilated patients preemptively.
- There is no clear-cut advantage for any opioid in the management of ventilated preterm neonates.
- Key questions remain regarding chronic pain assessment, long-term outcomes, and safety.

## SUMMARY

Pain management in neonates has made great strides over the last several years. Because of the serious short- and long-term adverse effects of pain and because of humanitarian reasons, all NICU patients deserve a focus on pain prevention, routine pain assessments, and evidence-based strategies for pain management, using both nonpharmacologic and pharmacologic approaches. Because pain strategies continue to fall short, future research should address systems-based practice and knowledge-transfer approaches on how to improve pain management in NICUs; how best to assess pain, especially prolonged or chronic pain; and how to incorporate the many variables affecting pain found in modern-day neonatology, such as light, sound, touch, parental separation, thermal stress, and extrauterine malnutrition. Continued emphasis on neonatal pain management research may help to decrease some of the adverse neurodevelopmental outcomes commonly found in our NICU graduates.

## REFERENCES

1. Unruh AM. Voices from the past: ancient views of pain in childhood. *Clin J Pain* 1992;8:247–54.
2. Wesson SC. Ligation of the ductus arteriosus: anesthesia management of the tiny premature infant. *AANA J* 1982;50:579–82.
3. Anand KJ, Hickey PR. Pain and its effects in the human neonate and fetus. *N Engl J Med* 1987;317:1321–9.
4. Rodkey EN, Pillai Riddell R. The infancy of infant pain research: the experimental origins of infant pain denial. *J Pain* 2013;14:338–50.
5. Watson JB. Psychology as the behaviorist views it. *Psychol Rev* 1913;20:158–77.
6. McGraw M. Neural maturation as exemplified in the changing reactions of the infant to pin prick. *Child Dev* 1941;12:31–42.
7. Dobbing J. Undernutrition and the developing brain. The relevance of animal models to the human problem. *Am J Dis Child* 1970;120:411–5.
8. Raiha N, Hjelt L. The correlation between the development of the hypophysial portal system and the onset of neurosecretory activity in the human fetus and infant. *Acta Paediatr* 1957;46:610–6.
9. Anand KJ, Brown MJ, Causon RC, et al. Can the human neonate mount an endocrine and metabolic response to surgery? *J Pediatr Surg* 1985;20:41–8.
10. Anand KJ, Hansen DD, Hickey PR. Hormonal-metabolic stress responses in neonates undergoing cardiac surgery. *Anesthesiology* 1990;73:661–70.
11. Anand KJ, Sippell WG, Aynsley-Green A. Randomised trial of fentanyl anaesthesia in preterm babies undergoing surgery: effects on the stress response. *Lancet* 1987;1:243–8.
12. Anand KJ, Sippell WG, Schofield NM, et al. Does halothane anaesthesia decrease the metabolic and endocrine stress responses of newborn infants undergoing operation? *Br Med J (Clin Res Ed)* 1988;296:668–72.
13. Anand KJ, Hickey PR. Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. *N Engl J Med* 1992;326:1–9.
14. Franck LS. A national survey of the assessment and treatment of pain and agitation in the neonatal intensive care unit. *J Obstet Gynecol Neonatal Nurs* 1987;16:387–93.
15. Krechel SW, Bildner J. CRIES: a new neonatal postoperative pain measurement score. Initial testing of validity and reliability. *Paediatr Anaesth* 1995;5:53–61.
16. Batton DG, Barrington KJ, Wallman C. Prevention and management of pain in the neonate: an update. *Pediatrics* 2006;118:2231–41.
17. Ferguson SA, Ward WL, Paule MG, et al. A pilot study of preemptive morphine analgesia in preterm neonates: effects on head circumference, social behavior, and response latencies in early childhood. *Neurotoxicol Teratol* 2012;34:47–55.
18. de Graaf J, van Lingen RA, Simons SH, et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates on children's functioning: five-year follow-up of a randomized controlled trial. *Pain* 2011;152:1391–7.
19. Grunau R, Tu MT. Long-term consequences of pain in human neonates. In: Anand KJ, Stevens B, McGrath P, editors. *Pain in neonates and infants*. 3rd edition. Philadelphia: Elsevier Science B.V.; 2007. p. 45–55.
20. Anand KJ, Palmer FB, Papanicolaou AC. Repetitive neonatal pain and neurocognitive abilities in ex-preterm children. *Pain* 2013;154:1899–901.

21. Doesburg SM, Chau CM, Cheung TP, et al. Neonatal pain-related stress, functional cortical activity and visual-perceptual abilities in school-age children born at extremely low gestational age. *Pain* 2013;154:1946–52.
22. Carbajal R, Rousset A, Danan C, et al. Epidemiology and treatment of painful procedures in neonates in intensive care units. *JAMA* 2008;300:60–70.
23. Johnston C, Barrington KJ, Taddio A, et al. Pain in Canadian NICUs: have we improved over the past 12 years? *Clin J Pain* 2011;27:225–32.
24. Taylor BJ, Robbins JM, Gold JI, et al. Assessing postoperative pain in neonates: a multicenter observational study. *Pediatrics* 2006;118:e992–1000.
25. Anand KJ, Aranda JV, Berde CB, et al. Summary proceedings from the neonatal pain-control group. *Pediatrics* 2006;117:S9–22.
26. Simons SH, van Dijk M, Anand KJ, et al. Do we still hurt newborn babies? A prospective study of procedural pain and analgesia in neonates. *Arch Pediatr Adolesc Med* 2003;157:1058–64.
27. Ranger M, Johnston CC, Anand KJ. Current controversies regarding pain assessment in neonates. *Semin Perinatol* 2007;31:283–8.
28. Sharek PJ, Powers R, Koehn A, et al. Evaluation and development of potentially better practices to improve pain management of neonates. *Pediatrics* 2006;118(Suppl 2):S78–86.
29. Walden M, Carrier C. The ten commandments of pain assessment and management in preterm neonates. *Crit Care Nurs Clin North Am* 2009;21:235–52.
30. Stapelkamp C, Carter B, Gordon J, et al. Assessment of acute pain in children: development of evidence-based guidelines. *Int J Evid Based Healthc* 2011;9:39–50.
31. Duhn LJ, Medves JM. A systematic integrative review of infant pain assessment tools. *Adv Neonatal Care* 2004;4:126–40.
32. Anand KJ. Pain assessment in preterm neonates. *Pediatrics* 2007;119:605–7.
33. Guedj R, Danan C, Daoud P, et al. Neonatal pain management is not the same during days and nights in intensive care units: analysis from the EPIPPAIN Study. *BMJ Open* 2014;4(2):e004086.
34. Anand KJ. Pain panacea for opiophobia in infants? *JAMA* 2013;309:183–4.
35. Anand KJ, Clark AE, Willson DF, et al. Opioid analgesia in mechanically ventilated children: results from the multicenter Measuring Opioid Tolerance Induced by Fentanyl study. *Pediatr Crit Care Med* 2013;14:27–36.
36. Anand KJ, Willson DF, Berger J, et al. Tolerance and withdrawal from prolonged opioid use in critically ill children. *Pediatrics* 2010;125:e1208–25.
37. Hummel P, van Dijk M. Pain assessment: current status and challenges. *Semin Fetal Neonatal Med* 2006;11:237–45.
38. Johnston CC, Stevens B. Pain assessment in newborns. *J Perinat Neonatal Nurs* 1990;4:41–52.
39. Stevens B, Johnston C, Petryshen P, et al. Premature infant pain profile: development and initial validation. *Clin J Pain* 1996;12:13–22.
40. Gibbins S, Stevens B, McGrath PJ, et al. Comparison of pain responses in infants of different gestational ages. *Neonatology* 2008;93:10–8.
41. Grunau RE, Oberlander T, Holsti L, et al. Bedside application of the Neonatal Facial Coding System in pain assessment of premature neonates. *Pain* 1998;76:277–86.
42. Holsti L, Grunau RE. Initial validation of the behavioral indicators of infant pain (BIIP). *Pain* 2007;132(3):264–72.
43. Ballantyne M, Stevens B, McAllister M, et al. Validation of the premature infant pain profile in the clinical setting. *Clin J Pain* 1999;15:297–303.

44. McNair C, Ballantyne M, Dionne K, et al. Postoperative pain assessment in the neonatal intensive care unit. *Arch Dis Child Fetal Neonatal Ed* 2004;89:F537–41.
45. Hummel P, Puchalski M, Creech SD, et al. Clinical reliability and validity of the N-PASS: neonatal pain, agitation and sedation scale with prolonged pain. *J Perinatol* 2008;28:55–60.
46. Hummel P, Lawlor-Klean P, Weiss MG. Validity and reliability of the N-PASS assessment tool with acute pain. *J Perinatol* 2010;30:474–8.
47. Lawrence J, Alcock D, McGrath P, et al. The development of a tool to assess neonatal pain. *Neonatal Netw* 1993;12:59–66.
48. Porter FL, Wolf CM, Miller JP. Procedural pain in newborn infants: the influence of intensity and development. *Pediatrics* 1999;104:e13.
49. Johnston CC, Stevens BJ, Franck LS, et al. Factors explaining lack of response to heel stick in preterm newborns. *J Obstet Gynecol Neonatal Nurs* 1999;28:587–94.
50. Johnston CC, Stevens BJ, Yang F, et al. Differential response to pain by very premature neonates. *Pain* 1995;61:471–9.
51. Ganzewinkel CJ, Anand KJ, Kramer BW, et al. Chronic pain in the newborn: toward a definition. *Clin J Pain* 2013. [Epub ahead of print].
52. van Dijk M, Koot HM, Saad HH, et al. Observational visual analog scale in pediatric pain assessment: useful tool or good riddance? *Clin J Pain* 2002;18:310–6.
53. Stevens BJ, Pillai Riddell R. Looking beyond acute pain in infancy. *Pain* 2006;124:11–2.
54. Pillai Riddell R, Racine N. Assessing pain in infancy: the caregiver context. *Pain Res Manag* 2009;14:27–32.
55. Holsti L, Grunau RE, Shany E. Assessing pain in preterm infants in the neonatal intensive care unit: moving to a 'brain-oriented' approach. *Pain Manag* 2011;1:171–9.
56. Ismail AQ, Gandhi A. Non-pharmacological analgesia: effective but underused. *Arch Dis Child* 2011;96:784–5.
57. Ernst E. Chiropractic manipulation for non-spinal pain—a systematic review. *N Z Med J* 2003;116:U539.
58. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. *JAMA* 1998;280:1569–75.
59. Bewley S, Ross N, Braillon A, et al. Clothing naked quackery and legitimising pseudoscience. *BMJ* 2011;343:d5960.
60. Hall RW. Anesthesia and analgesia in the NICU. *Clin Perinatol* 2012;39:239–54.
61. Holsti L, Grunau RE, Oberlander TF, et al. Prior pain induces heightened motor responses during clustered care in preterm infants in the NICU. *Early Hum Dev* 2005;81:293–302.
62. Holsti L, Grunau RE, Whifield MF, et al. Behavioral responses to pain are heightened after clustered care in preterm infants born between 30 and 32 weeks gestational age. *Clin J Pain* 2006;22:757–64.
63. Karlsson V, Heinemann AB, Sjors G, et al. Early skin-to-skin care in extremely preterm infants: thermal balance and care environment. *J Pediatr* 2012;161:422–6.
64. Cong X, Cusson RM, Walsh S, et al. Effects of skin-to-skin contact on autonomic pain responses in preterm infants. *J Pain* 2012;13:636–45.
65. Johnston C, Campbell-Yeo M, Fernandes A, et al. Skin-to-skin care for procedural pain in neonates. *Cochrane Database Syst Rev* 2014;(1):CD008435.

66. Morelius E, Theodorsson E, Nelson N. Salivary cortisol and mood and pain profiles during skin-to-skin care for an unselected group of mothers and infants in neonatal intensive care. *Pediatrics* 2005;116:1105–13.
67. McCain GC, Ludington-Hoe SM, Swinth JY, et al. Heart rate variability responses of a preterm infant to kangaroo care. *J Obstet Gynecol Neonatal Nurs* 2005;34:689–94.
68. Mitchell AJ, Yates CC, Williams DK, et al. Does daily kangaroo care provide sustained pain and stress relief in preterm infants? *J Neonatal Perinatal Med* 2013;6:45–52.
69. Mitchell AJ, Yates C, Williams K, et al. Effects of daily kangaroo care on cardiorespiratory parameters in preterm infants. *J Neonatal Perinatal Med* 2013;6:243–9.
70. Axelin A, Salanterä S, Lehtonen L. ‘Facilitated tucking by parents’ in pain management of preterm infants—a randomized crossover trial. *Early Hum Dev* 2006;82:241–7.
71. Cignacco EL, Sellam G, Stoffel L, et al. Oral sucrose and “facilitated tucking” for repeated pain relief in preterms: a randomized controlled trial. *Pediatrics* 2012;129:299–308.
72. de Freitas RL, Kubler JM, Elias-Filho DH, et al. Antinociception induced by acute oral administration of sweet substance in young and adult rodents: the role of endogenous opioid peptides chemical mediators and mu(1)-opioid receptors. *Pharmacol Biochem Behav* 2012;101:265–70.
73. Liaw JJ, Zeng WP, Yang L, et al. Nonnutritive sucking and oral sucrose relieve neonatal pain during intramuscular injection of hepatitis vaccine. *J Pain Symptom Manage* 2011;42:918–30.
74. Corbo MG, Mansi G, Stagni A, et al. Nonnutritive sucking during heelstick procedures decreases behavioral distress in the newborn infant. *Biol Neonate* 2000;77:162–7.
75. Mitchell A, Waltman PA. Oral sucrose and pain relief for preterm infants. *Pain Manag Nurs* 2003;4:62–9.
76. Bueno M, Yamada J, Harrison D, et al. A systematic review and meta-analysis of nonsucrose sweet solutions for pain relief in neonates. *Pain Res Manag* 2013;18:153–61.
77. O’Sullivan A, O’Connor M, Brosnahan D, et al. Sweeten, soother and swaddle for retinopathy of prematurity screening: a randomised placebo controlled trial. *Arch Dis Child Fetal Neonatal Ed* 2010;95:F419–22.
78. Kristoffersen L, Skogvoll E, Hafstrom M. Pain reduction on insertion of a feeding tube in preterm infants: a randomized controlled trial. *Pediatrics* 2011;127:e1449–54.
79. Holsti L, Grunau RE. Considerations for using sucrose to reduce procedural pain in preterm infants. *Pediatrics* 2010;125:1042–7.
80. Stevens B, Yamada J, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. *Cochrane Database Syst Rev* 2010;(1):CD001069.
81. Marin Gabriel MA, del Rey Hurtado de Mendoza B, Jimenez Figueroa L, et al. Analgesia with breastfeeding in addition to skin-to-skin contact during heel prick. *Arch Dis Child Fetal Neonatal Ed* 2013;98:F499–503.
82. Field T, Diego M, Hernandez-Reif M. Preterm infant massage therapy research: a review. *Infant Behav Dev* 2010;33:115–24.
83. Jain S, Kumar P, McMillan DD. Prior leg massage decreases pain responses to heel stick in preterm babies. *J Paediatr Child Health* 2006;42:505–8.
84. Diego MA, Field T, Hernandez-Reif M, et al. Preterm infant massage elicits consistent increases in vagal activity and gastric motility that are associated with greater weight gain. *Acta Paediatr* 2007;96:1588–91.

85. Procianoy RS, Mendes EW, Silveira RC. Massage therapy improves neurodevelopment outcome at two years corrected age for very low birth weight infants. *Early Hum Dev* 2010;86:7–11.
86. Woo YM, Lee MS, Nam Y, et al. Effects of contralateral electroacupuncture on brain function: a double-blind, randomized, pilot clinical trial. *J Altern Complement Med* 2006;12:813–5.
87. Taddio A, Katz J, Ilersich AL, et al. Effect of neonatal circumcision on pain response during subsequent routine vaccination. *Lancet* 1997;349:599–603.
88. Lander J, Brady-Fryer B, Metcalfe JB, et al. Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial [see comment]. *JAMA* 1997;278:2157–62.
89. Garcia OC, Reichberg S, Brion LP, et al. Topical anesthesia for line insertion in very low birth weight infants. *J Perinatol* 1997;17:477–80.
90. Kaur G, Gupta P, Kumar A. A randomized trial of eutectic mixture of local anesthetics during lumbar puncture in newborns. *Arch Pediatr Adolesc Med* 2003;157:1065–70.
91. Gradin M, Eriksson M, Holmqvist G, et al. Pain reduction at venipuncture in newborns: oral glucose compared with local anesthetic cream. *Pediatrics* 2002;110:1053–7.
92. Biran V, Gourrier E, Cimerman P, et al. Analgesic effects of EMLA cream and oral sucrose during venipuncture in preterm infants. *Pediatrics* 2011;128:e63–70.
93. Baxter AL, Ewing PH, Young GB, et al. EMLA application exceeding two hours improves pediatric emergency department venipuncture success. *Adv Emerg Nurs J* 2013;35:67–75.
94. Hui-Chen F, Hsiu-Lin C, Shun-Line C, et al. The effect of EMLA cream on minimizing pain during venipuncture in premature infants. *J Trop Pediatr* 2013;59:72–3.
95. Lemyre B, Hogan DL, Gaboury I, et al. How effective is tetracaine 4% gel, before a venipuncture, in reducing procedural pain in infants: a randomized double-blind placebo controlled trial. *BMC Pediatr* 2007;7:7.
96. O'Brien L, Taddio A, Lyszkiewicz DA, et al. A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain. *Paediatr Drugs* 2005;7:41–54.
97. Taddio A, Lee CM, Parvez B, et al. Contact dermatitis and bradycardia in a preterm infant given tetracaine 4% gel. *Ther Drug Monit* 2006;28:291–4.
98. Frey B, Kehrer B. Toxic methaemoglobin concentrations in premature infants after application of a prilocaine-containing cream and peridural prilocaine. *Eur J Pediatr* 1999;158:785–8.
99. Brisman M, Ljung BM, Otterbom I, et al. Methaemoglobin formation after the use of EMLA cream in term neonates. *Acta Paediatr* 1998;87:1191–4.
100. Taddio A, Ohlsson A, Einarson TR, et al. A systematic review of lidocaine-prilocaine cream (EMLA) in the treatment of acute pain in neonates. *Pediatrics* 1998;101:E1.
101. Essink-Tebbes CM, Wuis EW, Liem KD, et al. Safety of lidocaine-prilocaine cream application four times a day in premature neonates: a pilot study. *Eur J Pediatr* 1999;158:421–3.
102. Larsson BA, Norman M, Bjerring P, et al. Regional variations in skin perfusion and skin thickness may contribute to varying efficacy of topical, local anaesthetics in neonates. *Paediatr Anaesth* 1996;6:107–10.
103. Fitzgerald M, Millard C, McIntosh N. Cutaneous hypersensitivity following peripheral tissue damage in newborn infants and its reversal with topical anaesthesia. *Pain* 1989;39:31–6.

104. Schmidt B, Adelmann C, Stutzer H, et al. Comparison of sufentanil versus fentanyl in ventilated term neonates. *Klin Padiatr* 2010;222:62–6.
105. Saarenmaa E, Huttunen P, Leppaluoto J, et al. Alfentanil as procedural pain relief in newborn infants. *Arch Dis Child Fetal Neonatal Ed* 1996;75:F103–7.
106. Pokela ML, Koivisto M. Physiological changes, plasma beta-endorphin and cortisol responses to tracheal intubation in neonates. *Acta Paediatr* 1994;83:151–6.
107. e Silva YP, Gomez RS, Marcatto Jde O, et al. Early awakening and extubation with remifentanil in ventilated premature neonates. *Paediatr Anaesth* 2008;18:176–83.
108. Stoppa F, Perrotta D, Tomasello C, et al. Low dose remifentanyl infusion for analgesia and sedation in ventilated newborns. *Minerva Anestesiol* 2004;70:753–61.
109. Alencar AJ, Sanudo A, Sampaio VM, et al. Efficacy of tramadol versus fentanyl for postoperative analgesia in neonates. *Arch Dis Child Fetal Neonatal Ed* 2012;97:F24–9.
110. Quinn MW, Vokes A. Effect of morphine on respiratory drive in trigger ventilated pre-term infants. *Early Hum Dev* 2000;59:27–35.
111. Dyke MP, Kohan R, Evans S. Morphine increases synchronous ventilation in pre-term infants. *J Paediatr Child Health* 1995;31:176–9.
112. Anand KJ, Hall RW, Desai N, et al. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial [see comment]. *Lancet* 2004;363:1673–82.
113. Hall RW, Kronsberg SS, Barton BA, et al. Morphine, hypotension, and adverse outcomes among preterm neonates: who's to blame? Secondary results from the NEOPAIN trial. *Pediatrics* 2005;115:1351–9.
114. Menon G, Boyle EM, Bergqvist LL, et al. Morphine analgesia and gastrointestinal morbidity in preterm infants: secondary results from the NEOPAIN trial. *Arch Dis Child Fetal Neonatal Ed* 2008;93:F362–7.
115. Simons SH, van Dijk M, van Lingen RA, et al. Routine morphine infusion in pre-term newborns who received ventilatory support: a randomized controlled trial. *JAMA* 2003;290:2419–27.
116. Bellu R, de Waal K, Zanini R. Opioids for neonates receiving mechanical ventilation: a systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed* 2010;95:F241–51.
117. MacGregor R, Evans D, Sugden D, et al. Outcome at 5-6 years of prematurely born children who received morphine as neonates. *Arch Dis Child Fetal Neonatal Ed* 1998;79:F40–3.
118. Ranger M, Synnes AR, Vinall J, et al. Internalizing behaviours in school-age children born very preterm are predicted by neonatal pain and morphine exposure. *Eur J Pain* 2014;18:844–52.
119. de Graaf J, van Lingen RA, Valkenburg AJ, et al. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9 years of age? *Pain* 2013;154:449–58.
120. Angeles DM, Wycliffe N, Michelson D, et al. Use of opioids in asphyxiated term neonates: effects on neuroimaging and clinical outcome. *Pediatr Res* 2005;57:873–8.
121. El Sayed MF, Taddio A, Fallah S, et al. Safety profile of morphine following surgery in neonates. *J Perinatol* 2007;27:444–7.
122. Bouwmeester NJ, Hop WC, van Dijk M, et al. Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. *Intensive Care Med* 2003;29:2009–15.

123. Bouwmeester NJ, van den Anker JN, Hop WC, et al. Age- and therapy-related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. *Br J Anaesth* 2003; 90:642–52.
124. van Dijk M, Bouwmeester NJ, Duivenvoorden HJ, et al. Efficacy of continuous versus intermittent morphine administration after major surgery in 0-3-year-old infants; a double-blind randomized controlled trial. *Pain* 2002; 98:305–13.
125. Rouss K, Gerber A, Albisetti M, et al. Long-term subcutaneous morphine administration after surgery in newborns. *J Perinat Med* 2007;35:79–81.
126. Lynn AM, Nespeca MK, Bratton SL, et al. Ventilatory effects of morphine infusions in cyanotic versus acyanotic infants after thoracotomy. *Paediatr Anaesth* 2003;13:12–7.
127. Lynn AM, Nespeca MK, Bratton SL, et al. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. *Pain* 2000;88:89–95.
128. Lynn AM, Nespeca MK, Opheim KE, et al. Respiratory effects of intravenous morphine infusions in neonates, infants, and children after cardiac surgery. *Anesth Analg* 1993;77:695–701.
129. Carbajal R, Lenclen R, Jugie M, et al. Morphine does not provide adequate analgesia for acute procedural pain among preterm neonates. *Pediatrics* 2005;115: 1494–500.
130. Taddio A, Lee C, Yip A, et al. Intravenous morphine and topical tetracaine for treatment of pain in neonates undergoing central line placement. *JAMA* 2006; 295:793–800.
131. Cignacco E, Hamers JP, van Lingen RA, et al. Pain relief in ventilated preterms during endotracheal suctioning: a randomized controlled trial. *Swiss Med Wkly* 2008;138:635–45.
132. Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. *Br J Anaesth* 2008;101:680–9.
133. Aguado-Lorenzo V, Weeks K, Tunstell P, et al. Accuracy of the concentration of morphine infusions prepared for patients in a neonatal intensive care unit. *Arch Dis Child* 2013;98:975–9.
134. Guinsburg R, Kopelman BI, Anand KJ, et al. Physiological, hormonal, and behavioral responses to a single fentanyl dose in intubated and ventilated preterm neonates. *J Pediatr* 1998;132:954–9.
135. Lago P, Benini F, Agosto C, et al. Randomised controlled trial of low dose fentanyl infusion in preterm infants with hyaline membrane disease. *Arch Dis Child Fetal Neonatal Ed* 1998;79:F194–7.
136. Orsini AJ, Leef KH, Costarino A, et al. Routine use of fentanyl infusions for pain and stress reduction in infants with respiratory distress syndrome. *J Pediatr* 1996;129:140–5.
137. Gitto E, Pellegrino S, Manfrida M, et al. Stress response and procedural pain in the preterm newborn: the role of pharmacological and non-pharmacological treatments. *Eur J Pediatr* 2012;171:927–33.
138. Lago P. Premedication for non-emergency intubation in the neonate. *Minerva Pediatr* 2010;62:61–3.
139. Lucas da Silva PS, Oliveira Iglesias SB, Leao FV, et al. Procedural sedation for insertion of central venous catheters in children: comparison of midazolam/fentanyl with midazolam/ketamine. *Paediatr Anaesth* 2007;17:358–63.



140. Roberts KD, Leone TA, Edwards WH, et al. Premedication for nonemergent neonatal intubations: a randomized, controlled trial comparing atropine and fentanyl to atropine, fentanyl, and mivacurium. *Pediatrics* 2006;118:1583–91.
141. VanLooy JW, Schumacher RE, Bhatt-Mehta V. Efficacy of a premedication algorithm for nonemergent intubation in a neonatal intensive care unit. *Ann Pharmacother* 2008;42:947–55.
142. Lago P, Tiozzo C, Boccuzzo G, et al. Remifentanyl for percutaneous intravenous central catheter placement in preterm infant: a randomized controlled trial. *Paediatr Anaesth* 2008;18:736–44.
143. Pereira e Silva Y, Gomez RS, Marcatto Jde O, et al. Morphine versus remifentanyl for intubating preterm neonates. *Arch Dis Child Fetal Neonatal Ed* 2007;92:F293–4.
144. Aranda JV, Carlo W, Hummel P, et al. Analgesia and sedation during mechanical ventilation in neonates. *Clin Ther* 2005;27:877–99.
145. Hall RW, Boyle E, Young T. Do ventilated neonates require pain management? *Semin Perinatol* 2007;31:289–97.
146. Ancora G, Lago P, Garetti E, et al. Efficacy and safety of continuous infusion of fentanyl for pain control in preterm newborns on mechanical ventilation. *J Pediatr* 2013;163:645–51.e1.
147. Franck LS, Vilardi J, Durand D, et al. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation. *Am J Crit Care* 1998;7:364–9.
148. Ionides SP, Weiss MG, Angelopoulos M, et al. Plasma beta-endorphin concentrations and analgesia-muscle relaxation in the newborn infant supported by mechanical ventilation. *J Pediatr* 1994;125:113–6.
149. Saarenmaa E, Huttunen P, Leppaluoto J, et al. Advantages of fentanyl over morphine in analgesia for ventilated newborn infants after birth: a randomized trial. *J Pediatr* 1999;134:144–50.
150. Fahrenstich H, Steffan J, Kau N, et al. Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. *Crit Care Med* 2000;28:836–9.
151. Hammer GB, Ramamoorthy C, Cao H, et al. Postoperative analgesia after spinal blockade in infants and children undergoing cardiac surgery. *Anesth Analg* 2005;100:1283–8.
152. Pirat A, Akpek E, Arslan G. Intrathecal versus IV fentanyl in pediatric cardiac anesthesia. *Anesth Analg* 2002;95:1207–14 [Table of contents].
153. Hickey PR, Hansen DD. Fentanyl- and sufentanil-oxygen-pancuronium anesthesia for cardiac surgery in infants. *Anesth Analg* 1984;63:117–24.
154. Hickey PR, Hansen DD, Wessel DL, et al. Blunting of stress responses in the pulmonary circulation of infants by fentanyl. *Anesth Analg* 1985;64:1137–42.
155. Welzing L, Roth B. Experience with remifentanyl in neonates and infants. *Drugs* 2006;66:1339–50.
156. Marlow N, Weindling AM, Van Peer A, et al. Alfentanil pharmacokinetics in preterm infants. *Arch Dis Child* 1990;65:349–51.
157. Durrmeyer X, Vutskits L, Anand KJ, et al. Use of analgesic and sedative drugs in the NICU: integrating clinical trials and laboratory data. *Pediatr Res* 2010;67:117–27.
158. Blumer JL. Clinical pharmacology of midazolam in infants and children. *Clin Pharmacokinet* 1998;35:37–47.
159. Benini F, Farina M, Capretta A, et al. Sedoanalgesia in paediatric intensive care: a survey of 19 Italian units. *Acta Paediatr* 2010;99:758–62.

160. Arya V, Ramji S. Midazolam sedation in mechanically ventilated newborns: a double blind randomized placebo controlled trial [see comment]. *Indian Pediatr* 2001;38:967–72.
161. Anand KJ, Barton BA, McIntosh N, et al. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. *Neonatal Outcome and Prolonged Analgesia in Neonates. Arch Pediatr Adolesc Med* 1999;153:331–8 [Erratum appears in *Arch Pediatr Adolesc Med* 1999;153(8):895].
162. Shehab N, Lewis CL, Streetman DD, et al. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. *Pediatr Crit Care Med* 2009;10:256–9.
163. Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. *Cochrane Database Syst Rev* 2012;(6):CD002052.
164. Mekitarian Filho E, de Carvalho WB, Gilio AE, et al. Aerosolized intranasal midazolam for safe and effective sedation for quality computed tomography imaging in infants and children. *J Pediatr* 2013;163:1217–9.
165. Lane RD, Schunk JE. Atomized intranasal midazolam use for minor procedures in the pediatric emergency department. *Pediatr Emerg Care* 2008;24:300–3.
166. Ranger M, Celeste Johnston C, Rennick JE, et al. A multidimensional approach to pain assessment in critically ill infants during a painful procedure. *Clin J Pain* 2013;29:613–20.
167. Chess PR, D'Angio CT. Clonic movements following lorazepam administration in full-term infants. *Arch Pediatr Adolesc Med* 1998;152:98–9.
168. Treluyer JM, Zohar S, Rey E, et al. Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. *J Clin Pharm Ther* 2005;30:479–85.
169. de Wildt SN, de Hoog M, Vinks AA, et al. Pharmacodynamics of midazolam in pediatric intensive care patients. *Ther Drug Monit* 2005;27:98–102.
170. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. *Br J Clin Pharmacol* 2002;53:390–2.
171. Altintas O, Karabas VL, Demirci G, et al. Evaluation of intranasal midazolam in refraction and fundus examination of young children with strabismus. *J Pediatr Ophthalmol Strabismus* 2005;42:355–9.
172. Ince I, de Wildt SN, Wang C, et al. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. *Clin Pharmacokinet* 2013;52:555–65 [Erratum appears in *Clin Pharmacokinet* 2013;52(7):611 Note: Wang, Chengueng [corrected to Wang, Chenguang]].
173. Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. *Perfusion* 2005;20:309–15.
174. McDermott CA, Kowalczyk AL, Schnitzler ER, et al. Pharmacokinetics of lorazepam in critically ill neonates with seizures. *J Pediatr* 1992;120:479–83.
175. Gonzalez-Darder JM, Ortega-Alvaro A, Ruz-Franzi I, et al. Antinociceptive effects of phenobarbital in “tail-flick” test and deafferentation pain. *Anesth Analg* 1992;75:81–6.
176. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. *Drug Alcohol Depend* 2007;87:131–8.
177. Jenkins IA, Playfor SD, Bevan C, et al. Current United Kingdom sedation practice in pediatric intensive care. *Paediatr Anaesth* 2007;17:675–83.
178. Shah PS, Shah VS. Propofol for procedural sedation/anaesthesia in neonates. *Cochrane Database Syst Rev* 2011;(3):CD007248.

179. Ghanta S, Abdel-Latif ME, Lui K, et al. Propofol compared with the morphine, atropine, and suxamethonium regimen as induction agents for neonatal endotracheal intubation: a randomized, controlled trial [see comment]. *Pediatrics* 2007;119:e1248–55.
180. Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. *Br J Anaesth* 2007;99:864–70.
181. Welzing L, Kribs A, Eifinger F, et al. Propofol as an induction agent for endotracheal intubation can cause significant arterial hypotension in preterm neonates. *Paediatr Anaesth* 2010;20:605–11.
182. Chambliss CR, Anand KJ. Pain management in the pediatric intensive care unit. *Curr Opin Pediatr* 1997;9:246–53.
183. Betremieux P, Carre P, Pladys P, et al. Doppler ultrasound assessment of the effects of ketamine on neonatal cerebral circulation. *Dev Pharmacol Ther* 1993;20:9–13.
184. Anand KJ, Soriano SG. Anesthetic agents and the immature brain: are these toxic or therapeutic? [see comment]. *Anesthesiology* 2004;101:527–30.
185. Saarenmaa E, Neuvonen PJ, Huttunen P, et al. Ketamine for procedural pain relief in newborn infants. *Arch Dis Child Fetal Neonatal Ed* 2001;85:F53–6.
186. Barton KP, Munoz R, Morell VO, et al. Dexmedetomidine as the primary sedative during invasive procedures in infants and toddlers with congenital heart disease. *Pediatr Crit Care Med* 2008;9:612–5.
187. Carroll CL, Krieger D, Campbell M, et al. Use of dexmedetomidine for sedation of children hospitalized in the intensive care unit. *J Hosp Med* 2008;3:142–7.
188. Bejian S, Valasek C, Nigro JJ, et al. Prolonged use of dexmedetomidine in the paediatric cardiothoracic intensive care unit. *Cardiol Young* 2009;19:98–104.
189. Chrysostomou C, Sanchez De Toledo J, Avolio T, et al. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery? *Pediatr Crit Care Med* 2009;10:654–60.
190. Potts AL, Anderson BJ, Holford NH, et al. Dexmedetomidine hemodynamics in children after cardiac surgery. *Paediatr Anaesth* 2010;20:425–33.
191. Lam F, Bhutta AT, Tobias JD, et al. Hemodynamic effects of dexmedetomidine in critically ill neonates and infants with heart disease. *Pediatr Cardiol* 2012;33:1069–77.
192. Chrysostomou C, Morell VO, Wearden P, et al. Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia. *Congenit Heart Dis* 2013;8:48–56.
193. Diaz SM, Rodarte A, Foley J, et al. Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study. *Pediatr Crit Care Med* 2007;8:419–24.
194. Potts AL, Anderson BJ, Warman GR, et al. Dexmedetomidine pharmacokinetics in pediatric intensive care—a pooled analysis. *Paediatr Anaesth* 2009;19:1119–29.
195. Su F, Nicolson SC, Gastonguay MR, et al. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. *Anesth Analg* 2010;110:1383–92.
196. Vilo S, Rautiainen P, Kaisti K, et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. *Br J Anaesth* 2008;100:697–700.
197. Kubota T, Fukasawa T, Kitamura E, et al. Epileptic seizures induced by dexmedetomidine in a neonate. *Brain Dev* 2013;35:360–2.
198. Finkel JC, Quezado ZM. Hypothermia-induced bradycardia in a neonate receiving dexmedetomidine. *J Clin Anesth* 2007;19:290–2.

199. Berkenbosch JW, Tobias JD. Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin. *Pediatr Crit Care Med* 2003;4:203–5.
200. Mason KP, Zgleszewski SE, Prescilla R, et al. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. *Paediatr Anaesth* 2008;18:393–402.
201. Mason KP. Sedation trends in the 21st century: the transition to dexmedetomidine for radiological imaging studies. *Paediatr Anaesth* 2010;20:265–72.
202. Mason KP, Zurakowski D, Zgleszewski S, et al. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. *Paediatr Anaesth* 2010;20:516–23.
203. Chrysostomou C, Beerman L, Shiderly D, et al. Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study. *Anesth Analg* 2008;107:1514–22.
204. Mayers DJ, Hindmarsh KW, Gorecki DK, et al. Sedative/hypnotic effects of chloral hydrate in the neonate: trichloroethanol or parent drug? *Dev Pharmacol Ther* 1992;19:141–6.
205. Litman RS, Soin K, Salam A. Chloral hydrate sedation in term and preterm infants: an analysis of efficacy and complications. *Anesth Analg* 2010;110:739–46.
206. Novitskaya ES, Kostakis V, Broster SC, et al. Pain score assessment in babies undergoing laser treatment for retinopathy of prematurity under sub-tenon anaesthesia. *Eye* 2013;27:1405–10.
207. Menon G, Anand KJ, McIntosh N. Practical approach to analgesia and sedation in the neonatal intensive care unit. *Semin Perinatol* 1998;22:417–24.
208. Wong I, St John-Green C, Walker SM. Opioid-sparing effects of perioperative paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) in children. *Paediatr Anaesth* 2013;23:475–95.
209. van den Anker JN, Tibboel D. Pain relief in neonates: when to use intravenous paracetamol. *Arch Dis Child* 2011;96:573–4.
210. Nevin DG, Shung J. Intravenous paracetamol overdose in a preterm infant during anesthesia. *Paediatr Anaesth* 2010;20:105–7.
211. Howard CR, Howard FM, Weitzman ML. Acetaminophen analgesia in neonatal circumcision: the effect on pain. *Pediatrics* 1994;93:641–6.
212. Allegaert K, Rayyan M, De Rijdt T, et al. Hepatic tolerance of repeated intravenous paracetamol administration in neonates. *Paediatr Anaesth* 2008;18:388–92.
213. Truog R, Anand KJ. Management of pain in the postoperative neonate. *Clin Perinatol* 1989;16:61–78.
214. Shah V, Taddio A, Ohlsson A. Randomised controlled trial of paracetamol for heel prick pain in neonates. *Arch Dis Child Fetal Neonatal Ed* 1998;79:F209–11.
215. Morris JL, Rosen DA, Rosen KR. Nonsteroidal anti-inflammatory agents in neonates. *Paediatr Drugs* 2003;5:385–405.
216. Hopchet L, Kulo A, Rayyan M, et al. Does intravenous paracetamol administration affect body temperature in neonates? *Arch Dis Child* 2011;96:301–4.
217. Rod B, Monrignal JP, Lepoittevin L, et al. Traitement de la douleur postopératoire chez l'enfant en salle de réveil. Utilisation de la morphine et du propacetamol par voie intraveineuse. *Cah Anesthesiol* 1989;37:525–30.
218. Allegaert K, Anderson BJ, Naulaers G, et al. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. *Eur J Clin Pharmacol* 2004;60:191–7.

219. Anderson BJ, Pons G, Autret-Leca E, et al. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. *Paediatr Anaesth* 2005;15:282–92.
220. Hopkins CS, Underhill S, Booker PD. Pharmacokinetics of paracetamol after cardiac surgery [see comments]. *Arch Dis Child* 1990;65:971–6.
221. Autret E, Dutertre JP, Breteau M, et al. Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. *Dev Pharmacol Ther* 1993;20:129–34.
222. Lin YC, Sussman HH, Benitz WE. Plasma concentrations after rectal administration of acetaminophen in preterm neonates. *Paediatr Anaesth* 1997;7:457–9.
223. van Lingen RA, Deinum HT, Quak CM, et al. Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. *Clin Pharmacol Ther* 1999;66:509–15.
224. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. *Br J Clin Pharmacol* 2000;50:125–34.
225. Anderson BJ, van Lingen RA, Hansen TG, et al. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. *Anesthesiology* 2002;96:1336–45.
226. Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. *Arch Dis Child* 2011;96:575–80.
227. Fowlie PW. Prophylactic indomethacin: systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed* 1996;74:F81–7.
228. Sakhalkar VS, Merchant RH. Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin. *Indian Pediatr* 1992;29:313–8.
229. Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. *J Pediatr* 1997;131:549–54.
230. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus [see comment]. *N Engl J Med* 2000;343:674–81.
231. Varvarigou A, Bardin CL, Beharry K, et al. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. *JAMA* 1996;275:539–44.
232. Anand KJ, Hall RW. Pharmacological therapy for analgesia and sedation in the newborn. *Arch Dis Child Fetal Neonatal Ed* 2006;91:F448–53.
233. Allegaert K, Vanhole C, de Hoon J, et al. Nonselective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates. *Pediatr Nephrol* 2005;20:1557–61.
234. Naulaers G, Delanghe G, Allegaert K, et al. Ibuprofen and cerebral oxygenation and circulation. *Arch Dis Child Fetal Neonatal Ed* 2005;90:F75–6.
235. Johnston CC, Fernandes AM, Campbell-Yeo M. Pain in neonates is different. *Pain* 2011;152:S65–73.
236. Byrd PJ, Gonzales I, Parsons V. Exploring barriers to pain management in newborn intensive care units: a pilot survey of NICU nurses. *Adv Neonatal Care* 2009;9:299–306.
237. Cong X, Delaney C, Vazquez V. Neonatal nurses' perceptions of pain assessment and management in NICUs: a national survey. *Adv Neonatal Care* 2013;13:353–60.
238. Pillai Riddell RR, Stevens BJ, McKeever P, et al. Chronic pain in hospitalized infants: health professionals' perspectives. *J Pain* 2009;10:1217–25.

239. Spence K, Henderson-Smart D. Closing the evidence-practice gap for newborn pain using clinical networks. *J Paediatr Child Health* 2011;47:92–8.
240. Stevens B, Riahi S, Cardoso R, et al. The influence of context on pain practices in the NICU: perceptions of health care professionals. *Qual Health Res* 2011;21:757–70.
241. Aretz S, Licht C, Roth B. Endogenous distress in ventilated full-term newborns with acute respiratory failure. *Biol Neonate* 2004;85:243–8.
242. Grunau RE, Whitfield MF, Petrie J. Children's judgments about pain at age 8–10 years: do extremely low birthweight (< or = 1000 g) children differ from full birthweight peers? *J Child Psychol Psychiatry* 1998;39:587–94.
243. Boyle EM, Freer Y, Wong CM, et al. Assessment of persistent pain or distress and adequacy of analgesia in preterm ventilated infants. *Pain* 2006;124:87–91.
244. Giannantonio C, Sammartino M, Valente E, et al. Remifentanyl analgosedation in preterm newborns during mechanical ventilation. *Acta Paediatr* 2009;98:1111–5.
245. O'Mara K, Gal P, Ransommd JL, et al. Successful use of dexmedetomidine for sedation in a 24-week gestational age neonate. *Ann Pharmacother* 2009;43:1707–13.